What’s Propelling RELMADA THERAPEUTICS INC. COMMO (OTCMKTS:RLMD) After Lower Shorts Reported?

January 4, 2018 - By Peter Erickson

The stock of RELMADA THERAPEUTICS INC. COMMO (OTCMKTS:RLMD) registered a decrease of 14.81% in short interest. RLMD’s total short interest was 2,300 shares in January as published by FINRA. Its down 14.81% from 2,700 shares, reported previously. With 22,400 shares average volume, it will take short sellers 0 days to cover their RLMD’s short positions.

The stock increased 7.86% or $0.05501 during the last trading session, reaching $0.75501. About 6,220 shares traded. Relmada Therapeutics, Inc. (OTCMKTS:RLMD) has 0.00% since January 4, 2017 and is . It has underperformed by 16.70% the S&P500.

Relmada Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing drugs to treat central nervous system diseases, primarily depression and chronic pain in the United States. The company has market cap of $9.47 million. The Company’s lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. It currently has negative earnings. The firm is also developing include LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the management of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence indications; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy.

More notable recent Relmada Therapeutics, Inc. (OTCMKTS:RLMD) news were published by: Prnewswire.com which released: “Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the …” on June 28, 2017, also Prnewswire.com with their article: “Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its …” published on September 14, 2016, Prnewswire.com published: “Relmada Therapeutics to Mail Letter to Stockholders Highlighting Laidlaw …” on December 07, 2015. More interesting news about Relmada Therapeutics, Inc. (OTCMKTS:RLMD) were released by: Prnewswire.com and their article: “Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed …” published on August 10, 2015 as well as Marketwatch.com‘s news article titled: “Relmada Therapeutics Inc.” with publication date: August 06, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.